SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $15.5 million during the third quarter of 2013 which includes sales of its newly approved medication, RAVICTI® (glycerol phenylbutyrate) Oral Liquid and the first full quarter of sales of BUPHENYL® (sodium phenylbutyrate) Tablets and Powder following the company’s acquisition of that product.
Help employers find you! Check out all the jobs and post your resume.
